This week, for the seventh consecutive year, Servier, gold sponsor of LabCentral, hosted its Golden Ticket ceremony, awarding one “Golden Ticket” to a promising early-stage life-science company developing transformative solutions in areas of high unmet medical need.
The event featured a panel discussion on Servier’s AI vision, its impact across the pharmaceutical value chain and the group’s R&D strategy, followed by pitches from three shortlisted startups – NuCyRNA Therapeutics, Tinos Therapeutics and NeoSplice Therapeutics – to a jury of Servier experts.
Following deliberations, Tinos Therapeutics was selected as the 2026 Golden Ticket winner. Tinos Therapeutics is a preclinical-stage biotechnology company, pioneering a comprehensive epitranscriptomics drug development platform, with the ambition to translate RNA biology into a new class of transformative medicines. The company stood out for its differentiated scientific approach and its strong alignment with Servier’s ambition to accelerate innovation in precision medicine for patients with significant unmet needs.
“We feel deeply honored by this award from Servier and are elated about the increased visibility and awareness that it creates around the transformative power of RNA modification therapies.” says Dr. David Karambizi, co-founder and CEO at Tinos Therapeutics.
“At Tinos, we continue to move closer to realizing the development of first-in-class precision oncology asset classes centered on the epitranscriptome, which is a field of science that we believe is poised to redefine medicine.” says Dr. Nikos Tapinos, founder, President, and CSO at Tinos Therapeutics.
As part of the award, Tinos Therapeutics will receive a $50,000 credit toward space and services at LabCentral 700, valid over a 13-month period. In addition, Servier will provide access to its multidisciplinary expertise, supporting the company’s development through scientific, strategic and operational guidance.
Through the Golden Ticket, Servier continues to foster a dynamic innovation ecosystem and build meaningful partnerships with emerging biotech companies to help accelerate the development of next-generation therapies for patients.
